Patents by Inventor Byron H. Lee

Byron H. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ABCA1 DOWNREGULATION IN PROSTATE CANCER
    Publication number: 20210395834
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Application
    Filed: May 18, 2021
    Publication date: December 23, 2021
    Inventors: Angela H. Ting, Byron H. Lee
  • ABCA1 downregulation in prostate cancer
    Patent number: 11041212
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 22, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Angela H. Ting, Byron H. Lee
  • ABCA1 DOWNREGULATION IN PROSTATE CANCER
    Publication number: 20180355438
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Application
    Filed: July 30, 2018
    Publication date: December 13, 2018
    Inventors: Angela H. Ting, Byron H. Lee
  • ABCA1 downregulation in prostate cancer
    Patent number: 10047399
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: August 14, 2018
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Angela H. Ting, Byron H. Lee
  • ABCA1 DOWNREGULATION IN PROSTATE CANCER
    Publication number: 20140193814
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Application
    Filed: January 6, 2014
    Publication date: July 10, 2014
    Applicant: The Cleveland Clinic Foundation
    Inventors: Angela H. Ting, Byron H. Lee